Português
EnglishOn December 23, DingTalk and Shuimu Molecule partnered to launch the DingTalk version of Chat DD—a large-model application focused on the biopharmaceutical field—and announced their intention to deepen collaboration. This move aims to provide life science and biopharmaceutical companies with a professional knowledge engine based on multimodal large models, lowering the barriers to new drug development and advancing human health.
Jointly Exploring Deep AI Applications in Biopharmaceuticals
At the DingTalk AI 1.1 New Product Launch and Ecosystem Conference, Xing Jie, Chief Operating Officer of Beijing Shuimu Molecule Biotechnology Co., Ltd., was invited to attend and shared with Chen Hang, founder and CEO of DingTalk, the latest advancements in multimodal large models in the biopharmaceutical vertical domain, as well as the vision for their joint collaboration.
Shuimu Molecule is an innovative company incubated by the Artificial Intelligence Research Institute (AIR) at Tsinghua University in June 2023. It is dedicated to building foundational large models and intelligent agent platforms in the life sciences, leveraging advanced multimodal AI technologies to accelerate innovation across the entire biopharmaceutical and biomanufacturing value chain.
The company has independently developed the foundation model Chat DD FM® and the open-source model OpenBioMed, providing end-to-end support from drug立项, target discovery, molecular design to clinical research. Currently, Chat DD has been launched on DingTalk’s curated platform, serving dozens of domestic and international life science and pharmaceutical companies—including large pharmaceutical firms and small-to-medium-sized innovative enterprises—with ready-to-use AI tools and intelligent solutions that significantly enhance R&D efficiency.
A Decade-Long Partnership Rekindled: Building a New Paradigm for Intelligent R&D
Xing Jie noted that the collaboration between Shuimu Molecule and DingTalk dates back a decade, when the two companies jointly drove digital transformation in the pharmaceutical industry through a WuXi AppTec project, integrating personnel, logistics, and information flows on mobile platforms. This renewed partnership aims to deepen pharmaceutical R&D empowerment through multi-agent systems and, combined with innovative products like DingTalk Real, to bridge the connection between the digital and physical worlds, driving substantive industry transformation.
For a long time, new drug development has been constrained by the “10-year, $1 billion rule”—on average, it takes 10 years and $1 billion in investment. Today, the timeline has stretched to 15 years, and costs often exceed $2 billion. Xing Jie pointed out that traditional methods have reached their limits in terms of efficiency and cost, and AI has become the key to breaking the impasse. In the future, by building “virtual agent teams” that simulate different professional roles, autonomous collaboration in biological and clinical research can be achieved, dramatically shortening the R&D cycle and reducing costs.
According to Shuimu Molecule’s projections, by 2025, nearly 30% of drug R&D will incorporate AI technologies, growing at a rate of 5% annually; within five years, 1.5 new drugs entirely discovered by AI platforms are expected to emerge. AI is projected to boost R&D efficiency by 40%–60% and reduce costs by 30%–70%. Xing Jie emphasized: “AI is reshaping the landscape of pharmaceutical R&D. Through continued investment and co-creation of use cases, we believe that in the future, small, intelligent teams will be able to bring new drugs to market at extremely low cost.”
This collaborative innovation between Shuimu Molecule and DingTalk marks a new stage in the implementation of AI in vertical industries. The two parties will continue to deepen their cooperation, jointly driving the pharmaceutical industry toward intelligence, efficiency, and lower costs, injecting technological momentum into global health.
DomTech is DingTalk's officially designated service provider in Macau, specializing in providing DingTalk services to a wide range of customers. If you would like to learn more about DingTalk platform applications, you can contact our online customer service directly or reach us by phone at +852 95970612 or by email at cs@dingtalk-macau.com. We have an outstanding development and operations team with extensive market service experience, ready to provide you with professional DingTalk solutions and services!